Abstract:BACKGROUND: China has a high prevalence of hepatitis B virus (HBV), but most chronic hepatitis B (CHB) patients do not receive standardized antiviral therapy. There are few relevant reports addressing the outcomes of the large number of CHB patients who do not receive antiviral therapy.AIM: To observe the outcomes of long-term follow-up of patients with CHB without antiviral treatment.METHODS: This study included 362 patients with CHB and 96 with hepatitis B cirrhosis without antiviral treatment and with only liver protection and anti-inflammatory treatment from 1993 to 1998. The median follow-up times were 10 and 7 years, respectively. A total of 203 CHB and 129 hepatitis B cirrhosis patients receiving antiviral therapy were selected as the control groups. The median follow-up times were 8 and 7 years, respectively. Kaplan-Meier curves were used to analyze the cumulative incidence of hepatocellular carcinoma (HCC), and the Cox regression model was used to analyze the risk factors for HCC.RESULTS: Among the patients in the non-antiviral group, 16.9% had spontaneous decreases in HBV DNA to undetectable levels, and 32.8% showed hepatitis B e antigen (HBeAg) seroconversion. In the antiviral group, 87.2% of patients had undetectable HBV DNA, and 52% showed HBeAg seroconversion. Among CHB and hepatitis B cirrhosis patients, the cumulative incidence rates of HCC were 14.9% and 53.1%, respectively, in the non-antiviral group and were 10.7% and 31.9%, respectively, in the antiviral group. There was no difference between the two groups regarding the CHB patients (P = 0.842), but there was a difference between the groups regarding the hepatitis B cirrhosis patients (P = 0.026). The cumulative incidence rates of HCC were 1.6% and 22.3% (P = 0.022) in the groups with and without spontaneous HBeAg seroconversion, respectively. The incidence rates of HCC among patients with and without spontaneous declines in HBV DNA to undetectable levels were 1.6% and 19.1%, respectively (P = 0.051). There was no difference in the cumulative incidence of HCC between the two groups regarding the patients with drug-resistant CHB (P = 0.119), but there was a significant difference between the two groups regarding the patients with cirrhosis (P = 0.004). The Cox regression model was used for regression of the corrected REACH-B score, which showed that alanine aminotransferase > 400 U/L, history of diabetes, and family history of liver cancer were risk factors for HCC among men aged > 40 years (P < 0.05). Multifactorial analysis showed that a family history of HCC among men was a risk factor for HCC.CONCLUSION: Antiviral therapy and non-antiviral therapy with liver protection and anti-inflammatory therapy can reduce the risk of HCC. Antiviral therapy may mask the spontaneous serological response of some patients during CHB. Therefore, the effect of early antiviral therapy on reducing the incidence of HCC cannot be overestimated.

High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy

Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.

Association Between Hepatic Steatosis And Entecavir Treatment Failure In Chinese Patients With Chronic Hepatitis B

Chronic Hepatitis B Patients with High Liver Fibrosis Levels Should Receive Antiviral Treatment.

High Post-Treatment -Fetoprotein Levels And Aspartate Aminotransferase-To-Platelet Ratio Index Predict Hepatocellular Carcinoma In Hepatitis C Virus Decompensated Cirrhotic Patients With Sustained Virological Response After Antiviral Therapy

Histological Outcome for Chronic Hepatitis B Patients Treated with Entecavir Vs Lamivudine-Based Therapy.

Influence of Antiviral Treatment on the Efficacy and Prognosis of Compensated Hepatitis B Cirrhosis

Clinical cure and liver fibrosis reversal after postoperative antiviral combination therapy in hepatitis B-associated non-cirrhotic hepatocellular carcinoma: A case report

Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment

An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir

Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment

Long-Term Treatment with Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis

Recompensation of complications in patients with hepatitis B virus-related decompensated cirrhosis treated with entecavir antiviral therapy

Antiviral Effects of Entecavir in Patients with Hepatitis B Virus-Induced Decompensated Liver Cirrhosis

Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients

Incidence and Resolution of Steatohepatitis in Patients Receiving Entecavir for Chronic Hepatitis B

W1808 Regression of Fibrosis/Cirrhosis with Long-Term Entecavir Therapy in Chronic Hepatitis B (CHB) Patients with Baseline Bridging Fibrosis or Cirrhosis: Results from Studies ETV-022, -027 and -901

Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy

Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy